Lambert-Eaton myasthenic syndrome associated with idiopathic thrombocytopenic purpura and diffuse panbronchiolitis: Long-term remission after a course of intravenous immunoglobulin combined with low-dose prednisolone

American Journal of the Medical Sciences

Volumn 318, Issue 5, 1999, Pages 353-355

  Takata, T ^a,c   Koide, S ^a   Ogata, K ^a   Motomura, M ^b   Yoshimura, T ^b   Hanajima, R ^a   Sakurai, M ^a   Kanazawa, I ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KOBE UNIVERSITY   (Japan)

Author keywords

Diffuse panbronchiolitis; Idiopathic thrombocytopenic purpura; Intravenous immunoglobulin; Lambert Eaton myasthenic syndrome; Prednisolone

Indexed keywords

CHOLINESTERASE INHIBITOR; IMMUNOGLOBULIN; PREDNISOLONE;

ADULT; ARTICLE; BRONCHIOLITIS; CASE REPORT; EATON LAMBERT SYNDROME; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTHERAPY; MYASTHENIA; NEUROMUSCULAR TRANSMISSION; REMISSION;

EID: 0033499183     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9629(15)40652-4     Document Type: Article

References (13)

1. O'Neill JH, Murray NMF, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. Brain. 1988;111:577-96.
2. Deodhar A, Norden J, So Y, et al. The association of systemic lupus erythematosus and Lambert-Eaton myasthenic syndrome. J Rheumatol 1996;23:1292-4.
3. Tsuchiya N, Sato M, Uesaka Y, et al. Lambert-Eaton myasthenic syndrome associated with Sjrens syndrome and discoid lupus erythematosus. Scand J Rheumatol 1993;22: 302-4.
4. Motomura M, Johnson I, Lang B, et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995;58:85-7.
5. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332: 1467-74.
6. Tarantino, MD, Goldsmith, G. Treatment of acute immune thrombocytopenic purpura. Semin Hematol 1998;35:28-35.
7. Sugiyama Y. Diffuse panbronchiolitis. Clin Chest Med 1993; 14:765-72.
8. Sanders DB. Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanism, and update on therapy. Ann Neurol 1995;37(suppl 1):S63-73.
9. Bain PG, Motomura M, Newsome-Davis J, et al. Effect of intraveous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996;47:678-83.
10. Muchnik S, Losavio S, Vidai A, et al. Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve 1997;20:674-8.
11. Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Int Med 1997;126:721-30.
12. van der Merché FGA, van Doorn PA. The current place of high-dose immunoglobulin in the treatment of neuromuscular disorders. Muscle Nerve 1997;20:136-47.
13. Evoli A, Palmisani MT, Bartoccioni E, et al. High-dose intravenous immunoglobulin in myasthema gravis. Ital J Neurol Sci 1993;14:233-7.